Critical Diagnostics

Click on any article to go to a peer-reviewed abstract

2014	Gruson, D, Lepoutre, T, Ahn, SA, Rousseau, MF. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. January 2014 (10.1016/j.ijcard.2013.12.101)
	Bayes-Genis, A, de Antonio, M, Vila, J, Penafiel, J, Galan, A, Barallat, J, Zamora, E, Urrutia, A, Lupon, J. Head-toHead Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. ST2 Versus Galectin-3. JACC, 2014, Jan 158-66.
	Ojji, DB, Opie, LH, Lecour, S, Lacerda, L, Adeyemi, OM, Sliwa, K. The Effect of Left Ventricular Remodelling on Soluble ST2 in a Cohort of Hypertensive Subjects. J. Human Hyp. 2014, 1-6.
	Januzzi, J, van Kimmenade, R.R.J. Importance of Rigorous Evaluation in Comparative Biomarker Studies. JACC 2014.
2013	Ho, J, Larson, M.G., Bhorbani, A, Cheng, S, Vasan, R.S., Wang, T.J., Januzzi, Jr., J.L. Soluble ST2 Predicts Elevated SBP In The Community. J Hypertens 2013;31:0000-0000
	Lassus,, J, Gayat, E, Mueller, C, Peacock, W.F., Spinar, J, Harjola, VP, van Kimmenade, R, Pathak, A, Mueller, T, diSomma, S, Metra, M, Pascual-Figal, D, Laribi, S, Loeart, D, Nouira, S, Sato, N, Potocki, M, Parenica, J, Collet, C, Cohen-Solal, A, Januzzi, J.L., Mebazaa, A. Incremental Value of Biomarkers To Clinical Variables For Mortality Prediction In Acutely Decompensated Heart Failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) Study. Int J Cardiol (2013).
	Breidhardt, T, Balmelli, C, Twerenbold, R, Mosimann, T, Espinola, J, Haaf, P, Thalmann, G, Moehring, B, Mueller, M, Meller, B, Reichlin, T, Murray, K, Ziller, R, Benkert, P, Osswald, S, Mueller, C. Heart Failure Therapy-Induced Early ST2 Changes May Offer Long-Term Therapy Guidance. J. Card. Fail. 2013 Dec;19(12):821-8.
	Felker, G. Michael, Fiuzat, M, Thompson, V, Shaw, L, Neely, M.L., Adams, K.F., Whellan, D.J., Donahue, M.P., Ahmad, T., Kitzman, W.D., Pina, I.L., Zannad, F, Kraus, W.E., O’connor, C.M. Soluble ST2 in Ambulatory Patients with Hearth Failure: Association with Functional Capacity and Long-Term Outcomes. Circ Heart Fail. Oct 2013.
	Gaggin, H, Motiwala, S, Bhardwaj, A, Parks, K.A., Januzzi, J. Soluble Concentrations of the Interleukin Receptor Family Member ST2 and Beta Blocker Therapy in Chronic Heart Failure. Circ Heart Fail. Oct 2013.
	Dunlay, SM, Jaffe, AS. Are Biomarkers the Answer to the Heart Failure Readmissions Problem? Clin Chem 2013;59:737-739.
	James L. Januzzi, Benjamin D. Horne, Stephanie A. Moore, Oxana Galenko, Gregory L. Snow, Kimberly D. Brunisholz, Joseph B. Muhlestein, Rami Alharethi, John F. Carlquist, Deborah Budge, Kismet Rasmussen, and Abdallah G. Kfoury. Inteleukin Receptor Family Member ST2 Concentrations in Patients Following Heart Transplantation.
	James L. Januzzi. ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside
	Josep Lupón, MD, PhD; Marta de Antonio, MD; Amparo Galán, MD, PhD;Joan Vila, MSc; Elisabet Zamora, MD, PhD; Agustín Urrutia, MD, PhD;and Antoni Bayes-Genis, MD, PhD Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment.
2012	Wang T, Wollert K, Larson M, Coglianese E, McCabe E, Cheng S, Ho J, Fradley M, Ghorbani A, Xanthakis V, Kempf T, Benjamin E, Levy D, Vasan R, Januzzi J. Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study. Circ. AHA journals. August 2012.
	Ky B, French B, Levy W, Sweitzer N, Fang J, Wu AH, Goldberg L, Jessup M, Cappola T. Multiple Biomarkers for Risk Prediction in Chronic Heart Failure. Circ. Heart Fail. Epub Mar. 2012.
	Broch K, Ueland T, Nymo S, Kjekshus J, Hulthe J, Muntendam P,8, McMurray J, Wikstrand J, Cleland J, Aukrus P, Gullestad L. Soluble ST2 is Associated with Adverse Outcome in Patients with Heart Failure of Ischaemic Aetiology. Euro J. of Heart Fail. Epub Feb, 2012.
	Bayes-Genis A, Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R, Cano L, Gonzalez B, Diez C, Pascual T, Elosua R, Lupon J. Combined use of High-Sensitivity ST2 and NTproBNP to Improve the Prediction of Death in Heart Failure. Euro J. of Heart Fail. 2012 Jan;14(1):32-38.
	Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J. Card. Failure. 2012 Apr;18(4):304-10
	Kohli P, Bonaca M, Kakkar R, Kudinova A, Scirica B, Sabatine M, Murphy S, Braunwald E, Lee R, Morrow D. Role of ST2 in Non–ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. Clin. Chem. 2012 58(1).
2011	Pascual-Figal D, Manzano-Fernandez S, Boronat M, Casas T, Garrido I, Bonaque J, Pastor-Perez F, Valdes M, Januzzi JL. Soluble ST2, High-Sensitivity Troponin T and N-terminal pro-B-type Natriuretic Peptide: Complementary Role for Risk Stratification in Acutely Decompensated Heart Failure. Euro J. Heart Fail. 2011 Jul;13(7):718-25.
	Shah K, Kop W, Christenson R, Diercks D, Henderson S, Hanson, K, Li S-Y, deFilippi C. Prognostic Utility of ST2 in Patients with Acute Dyspnea and Preserved Left Ventricular Ejection Fraction. Clin Chem. 2011 Jun;57(6):874-82.
	Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries D, Tang WH, WuAH, Fang JC, Boxer R, Sweitzer NK, Levy W, Goldberg L, Jessup M, Cappola TP.High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure.Circulation Heart Fail.2011 Jan 19[Epub 2010 Dec 22]PubMed PMID: 21178018.
2010	Bonaca MP, Kudinova A, Kakkar R, Scirica BS, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA. Abstract 20145: ST2 and the Risk of CV Death or Heart Failure in Patients with Non-ST elevation Acute Coronary Syndromes (NSTE-ACS): Observations from MERLIN-TIMI 36.Circulation 2010 Nov 23;122:A20145.
	Khan ADM, Reingold JS, Scherrer-Crosbie M, Chen-Tournoux A, Barth M, McCabe EL, Arora P, Cange A, Ryan A, Durrani S, Newton-Cheh C, Gerszten RE, Kaplan LM, Wang TJ. Abstract 19727: Improvements in Cardiometabolic Biomarkers Occur Early after Bariatric Surgery.Circulation 2010 Nov 23;122:A19727.
	Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries D, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy W, Goldberg L, Jessup M, Cappola TP. Abstract 19376: High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure.Circulation 2010 Nov 23;122:A19376.
	Moore SA, Horne BD, Januzzi JL, Galenko O, Snow GL, Brunisholz KD, Muhlestein JB, Alharethi R, Carlquist J, Budge D, Kfoury AG. Abstract 17331: Utility of the Interleukin Receptor Family Member ST2 in Predicting Allograft Rejection and Long-term Survival After Heart Transplantation.Circulation 2010 Nov 23;122:A17331.
	Daniels L, Clopton P, Iqbal N, Tran K, Maisel A. Association of ST2 Levels with Cardiac Structure and Function and Mortality in Outpatients. Am Heart J. 2010 Oct;160 (4):721-8.PubMed PMID: 20934567.
	Januzzi JL Jr, Rehman S, Mueller T, van Kimmenade RR, Lloyd-Jones DM. Importance of Biomarkers for Long-term Mortality Prediction in Acutely Dyspneic Patients.Clin Chem. 2010 Dec; 56(12):1814-21. Epub 2010 Oct 4.PubMed PMID:20921266.
	Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdés Chávarri M, Ordóñez-Llanos J. Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure.Rev Esp Cardiol. 2010 Oct;63(10):1171-1178.PubMed PMID: 20875357.
	Socrates T, Defilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M, Potocki M, Reiter M, Arenja N, Heinisch C, Meissner J, Jaeger C, Christenson R, Mueller C. Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med. 2010 Nov; 268 (5): 493-500. Epub 2010 Jul 15. PubMed PMID: 20804518.
	Taub PR, Gabbai-Saldate P, Maisel A. Biomarkers of heart failure. Congest Heart Fail.2010 Jul;16 Suppl 1:S19-24.PubMed PMID: 20653707.
	Lu J, Snider JV, Grenache DG. Establishment of reference intervals forsoluble ST2 from a United States population.Clin Chim Acta. 2010 Nov11;411(21-22):1825-6. Epub 2010 Jul 21. PubMed PMID: 20654603.
	Dieplinger B, Egger M, Poelz W, Haltmayer M, Mueller T. Long-term stability of soluble ST2 in frozen plasma samples.Clin Biochem. 2010 Sep;43(13-14):1169-70. Epub 2010 Jun 8. PubMed PMID: 20534378.
	Chan D, Ng LL. Biomarkers in Acute Myocardial Infarction. BMC Med. 2010 Jun 7;8:34.Review. PubMed PMID: 20529285; PubMed Central PMCID: PMC2898678.
	Bhardwaj A, Januzzi JL Jr. ST2: a novel biomarker for heart failure.Expert Rev Mol Diagn. 2010 May;10(4):459-64. Review. PubMed PMID: 20465500.
	de Couto G, Ouzounian M, Liu PP. Early Detection of Myocardial Dysfunction and Heart Failure.Nat Rev Cardiol.2010;7(6):334-44.Review. PubMed PMID: 20458341.
	Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, James SK. ST2 and mortality in non-ST-segment elevation acute coronary syndrome.Am Heart J. 2010 May;159(5):788-94.PubMed PMID: 20435187.
	Shah RV, Januzzi JL Jr. ST2: a Novel Remodeling Biomarker in Acute and Chronic Heart Failure.Curr Heart Fail Rep. 2010 Mar;7(1):9-14. Review. PubMedPMID: 20425491.
	Christopher R. DeFilippi, Keyur Shah, Robert Christenson, Sue Hender, and Willem Kop. ST2 for stratifying preserved ejection fraction patients with shortness of breath.J Am Coll Cardiol, 2010March 9; 55: A17.E164.
	Christopher R. DeFilippi, Robert Christenson, Keyur Shah, Sue Henderson, and Willem Kop. Change in ST2 level: refining risk stratification in the dyspnea patient.J Am Coll Cardiol, 2010March 9; 55: A29.E275.
	Thenral Socrates, Christopher DeFilippi, Tobias Reichlin, Raphael Twerenbold, Tobias Breidhardt, Markus Noveanu, Mihael Potocki, Robert Christenson, and Christian Mueller. Interleukin family member ST2 and mortality in acute dyspnea.J Am Coll Cardiol, 2010March 9; 55: A21.E195.
	Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic Value of Established and Novel Biomarkers in Patients with Shortness of Breath Attending an Emergency Department. Clin Biochem. 2010 Jun;43(9):714-9.Epub 2010 Feb 11. PubMed PMID: 20153308.
	Moore S, Januzzi J. Found in Translation: Soluble ST2 and Heart Disease. J. Am. Coll. Cardiol. 2010;55;251-253. PubMed PMID: 20117404.
	Weir AP, Miller A, Murphy G, Clements S, Steedman T, Connell J, McInnes I, Dargie H, McMurray J. Serum Soluble ST2: A Potential Novel Mediator in Left Ventricular and Infarct Remodeling After Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2010;55;243-250. PubMed PMID: 20117403.
2009	Pascual-Figal D, Ordoñez-Llanos J, Tornel P, Vázquez R, Valdés M, Cinca J, Bayes de Luna A, Bayes-Genis A.Soluble ST2 for Predicting Sudden Cardiac Death in Patients with ChronicHeart Failure and Left Ventricular Systolic Dysfunction. J. Am. Coll. Cardiol. 2009 Dec 1;54;2174-2179. PubMed PMID: 19942089.
	Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT.Interleukin-33 prevents apoptosis and improves survival after experimentalmyocardial infarction through ST2 signaling.Circ Heart Fail. 2009Nov;2(6):684-91. Epub 2009 Sep 22. PubMed PMID: 19919994.
	Lori B. Daniels, Paul Clopton, Kimberly Tran, and Alan S. Maisel. Abstract 2370: Association of ST2 Levels With Cardiac Structure and Function and Mortality in Outpatients.Circulation, 2009 Nov; 120: S634.
	Pascual-Figal, DA, Garrido IP, Blanco RM, Sanchez-Mas J, Minguela A, Gracia R, Martínez MD, Ordoñez J, Bayes-Genis A, Valdes M. Characteristics of the Interleukin Family Biomarker ST2 after Heart Transplantation. ESC Conference Abstract 2009.
	Shah R, Chen-Tournoux A, Picard M, van Kimmenade R, Januzzi J. Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients with Acute Dyspnea. Circ Heart Fail. 2009 Jul;2:311-319. Epub 2009 May 14. PubMed PMID: 19808354.
	Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay.Clin Chim Acta. 2009 Nov;409(1-2):33-40. Epub 2009 Aug 20. PubMed PMID: 19699192.
	Kakkar R, Lee RT. ST2 and Adrenomedullin in Heart Failure.Heart Fail Clin. 2009 Oct;5(4):515-27.PubMed PMID: 19631176.
	Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of Novel Biomarkers for the Diagnosis of Acute Destabilised Heart Failure in Patients with Shortness of Breath. Heart. 2009 Sep;95(18):1508-13. Epub 2009 Jun 11. PubMedPMID: 19525245.
	Weinberg EO. ST2 Protein in Heart Disease: From Discovery to Mechanisms and Prognostic Value.Biomark Med.2009;3(5):495-511.PubMed PMID: 20477519.
2008	Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel A, Fitzgerald R. Serial Sampling of ST2 Predicts 90-day Mortality Following Destabilized Heart Failure. J Cardiac Failure 2008:14(9):732-738.
	Rehman S, Mueller T, Januzzi J. Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients with Acute Heart Failure. J. Am. Coll. Cardiol. 2008;52(18):1458-1465.
	Díez J. Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure: Future Areas of Research.JACC 2008 Oct 28;52(18):1466-7.
	Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-terminal Prohormone B-type Natriuretic Peptide in Patients with ST-elevation Myocardial Infarction. Circulation. 2008;117(15):1936-44.
	Kakkar R, Lee R. The IL-33/ST2 Pathway: Therapeutic Target and Novel Biomarker. Nature Reviews, Drug Discovery. 2008; 7:827-840.
	Rehman S, Martinez-Rumayor A, Mueller T, Januzzi J. Independent and Incremental Prognostic Value of Multimarker Testing in Acute Dyspnea: Results From the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.Clinica Chemica Acta. 2008;392:41-45.
	Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased Plasma Concentrations of Soluble ST2 are Predictive for 1-Year Mortality in Patients with Acute Destabilized Heart Failure.Clinical Chemistry. 2008;54(4):752-756.
	Palmer G, Lipsky B, Smithgall M, Meininger D, Siu S, Talabot-Ayer D, Gabay C, Smith D. The IL-1 Receptor Accessory Preotein (AcP) is Required for IL-33 Signaling and Soluble AcP Enhances the Ability of Soluble ST2 to Inhibit IL-33.Cytokine. 2008; 42(3):358-64.
	Martinez-Rumayor A, Camargo C, Green S, Baggish A, O’Donoghue M, Januzzi J. Soluble ST2 Plasma Concentrations Predict 1-Year Mortality in Acutely Dyspneic Emergency Department Patients with Pulmonary DiseaseAJCP 2008;130(4):578-584.
2007	Januzzi J, Peacock W, Maisel A, Chae C, Jesse R, Baggish A, O’Donoghue M, Sakhuja R, Chen A, van Kimmenade R, Lewandroski K, Lloyd-Jones D, Wu A. Measurement of the Interleukin Family Member ST2 in Patients with Acute Dyspnea: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.J. Am. Coll. Cardiol. 2007;50(7):607-613.
	Weinberg E, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee R. Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker.Circulation. 2003;107:721-726.
	Brown A, Wu A, Clopton P, Robey J, Hollander J. ST2 in Emergency Department Chest Pain Patients With Potential Acute Coronary Syndromes.Ann. Emerg. Med. 2007; 50(2):153-8.
	Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA.IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex.J Immunol. 2007;179(4):2551-5.
	Sanada S, Hakuno D, Higgins L, Schreiter E, McKenzie A, Lee R. IL-33 and ST2 Comprise a Critical Biomechanically Induced and Cardioprotective Signaling System.J. Clin. Invest. 2007; 117(6):1538-49.
Prior to 2007	Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan T, Zurawski G, Moshrefi M, Qun J, Li X, Gorman D, Bazan J, Kastelein R. IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-RelatedProtein ST2 and Induces T Helper Type 2-Associated Cytokines.Immunity. 2005;23:479-490.
	Shimpo M, Morrow D, Weinberg E, Sabatine M, Murphy S, Antman E, Lee R. Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction.Circulation. 2004;109:2186-2190.
	Weinberg E, Shimpo M, Keulenaer G, MacGillivray C, Tominaga S, Solomon S, Rouleau JL, Lee R. Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction.Circulation2002;106:2961-2966.

heart failure today
Winter 2013 Issue

To order your copy, please click here

Click here for online version

30-day rehospitalization
White Paper

To view a copy, please click here